James I'm not your biggest fan but be safe with both of those companies you mentioned. CHTP is prime to get a Adam F balst article sometime soon, as was the case with CPRX recently. Also CYTK may in fact double from current valuation based on hopium but be cautious holding through data read out. Good luck.
Hey guys, RMTI is a great company and still has great long term prospects. If you have cash sitting around in boring little companies with no near term catalysts and you would like a strong LT prospect, check out NSPR. It is my largest holding at this point. Check out Seeking Alpha for my article and then read through the companies website for more information. As always, please do your own DD and never rely on me or anyone to do your research for you.
RMTI still has the calcitriol news pending and the Nov ASN conference will surely give it a nice bump. Clinicians are excited about Triferic and the share price will continue to reflect that. Good luck to you all.
search Rockwell Medical A Highly undervalued gem. I have written two articles with scientific data and explained the KERX connection in the last article. Its not worth my time to rewrite a brand new article to refute his dubious statements that he tried to pass off as facts. I've been on board since the stock was below $4 and this is the same excrement that I have heard since then. Good luck to you!
You are very welcome. Rockwell applied for "manufacturing approval" for Calcitriol on April 1st, 2013. FDA gave Rockwell expedited review, historically it takes the FDA 6 months to approve the drug pending application in such circumstances. Keep in mind that this is not a NEW DRUG APPLICATION (NDA), its a Marketing approval. The chances of approval in my opinion are approximately 99% and are expected by October 1st.
I'm glad you guys liked it. There is a lot of panic from the short side in regards to Rockwell and from those investors who missed the upswings. As I said before, when the stock was below $4, Rockwell is highly undervalued.
Summer Street analysts, who did the most thorough research, predict that Triferic will have sale of less than 200 million and put a price target of $25. Keep in mind the the IV Iron market is $680 million the US and $1.5 billion world wide. Triferic will become the standard of care for anemic patients on dialysis.
Triferic is safer in regards to Allergic reactions (NONE in over 100,000 patient doses), does not cause liver toxicity and inflammatory response in the body from increased ferritin levels, etc. Triferic will complete with black boxed drugs for patients and I can bet the farm that Doctors will prescribe a safer drug over a potentially dangerous one.
If you have any questions, check out the article and post them there and I will do my best to respond in a timely manner.
P.S. don't forget the $350 million market Rockwell will be targeting with Calcitriol. Since Calcitriol is in IV form, it has a better response in the body due to increased bio-availability of the drug.